Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)

Overall survival benefit with the addition of olaratumab to doxorubicin for patients with STS in the randomized Phase II JGDG trial
3:42 minutes.

Classification, incidence and management of sarcomas

Integration of the recently FDA-approved agents trabectedin and eribulin into the treatment algorithms for metastatic liposarcoma and leiomyosarcoma

Recent FDA approval of olaratumab in combination with doxorubicin and integration into the treatment algorithm for advanced STS

Role of tyrosine kinase inhibitors and immune checkpoint inhibitors in STS